Subscribe for full access
Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Recommendation Rating
2.33
1
2
3
4
5
1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL
Analysts’ Price Targets
Mean 7.5
Low: 7
High: 8
Total Analysts: 3
Company Profile
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for kidney diseases, such as acute ischemic stroke (AIS) and chronic kidney disease (CKD). The Company’s lead product, DM199, is an active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein for the treatment of AIS and CKD, including hypertensive nephrosclerosis (hypertension). KLK1 is a serine protease (protein) that plays a role in the regulation of diverse physiological processes, including blood flow, inflammation, fibrosis, oxidative stress, and neurogenesis, via a molecular mechanism that increases the production of nitric oxide and prostaglandin. It has also identified a potential treatment for inflammatory diseases, DM300, which is in the early preclinical stage of development.
We do our best to screen stocks as accurately as possible. Please let us know in the Community if you spot an error or find something questionable. Jazaak Allahu khairan.
